Armistice Capital Increases Stake in Biodexa Pharmaceuticals (BDRX) to 9.99%

Armistice Capital, LLC and its managing member, Steven Boyd, have filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Biodexa Pharmaceuticals Plc (BDRX). As of the event date on March 31, 2026, the reporting persons reported beneficial ownership of 187,975 American Depositary Shares, which represents 9.99% of the company's class of securities. This indicates a significant increase from a previously reported 0.0% position. The shares are held directly by the Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Consequently, both Armistice Capital and Steven Boyd may be deemed to share voting and dispositive power over the shares. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing also clarifies that the Master Fund has the right to receive dividends and sale proceeds from these securities.